Nicotinamide Bp

This article explores the use of Nicotinamide BP, a form of vitamin B3, in clinical trials as part of a multivitamin formulation. While the primary focus of the trial is on a different drug (eplontersen) for treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), Nicotinamide BP is included as one of the active substances in a multivitamin capsule used in the study. We’ll examine the potential benefits and implications of using this vitamin combination in clinical research for heart-related conditions.

Table of Contents

What is Nicotinamide BP?

Nicotinamide BP, also known as niacinamide, is a form of vitamin B3. It is one of the active ingredients found in Concavit Capsules, a multivitamin supplement[1]. The “BP” in the name stands for “British Pharmacopoeia,” which indicates that the substance meets specific quality standards[1].

Uses of Nicotinamide BP

Nicotinamide BP is primarily used as a vitamin supplement. It plays several important roles in the body, including:

  • Supporting cellular energy production
  • Helping maintain healthy skin
  • Contributing to the proper functioning of the nervous system
  • Assisting in DNA repair

In the context of the clinical trial mentioned, Nicotinamide BP is part of a multivitamin supplement given to patients with a condition called Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)[1]. This is a serious heart condition where abnormal proteins build up in the heart, affecting its function.

How Nicotinamide BP is Administered

In the clinical trial, Nicotinamide BP is administered as part of Concavit Capsules, which are soft capsules taken orally. The dosage mentioned in the trial is approximately 3000 IU (International Units) of vitamin A or a similar dose, which may be taken either as a single vitamin A supplement or as part of a multivitamin[1].

Clinical Trials and Research

The clinical trial mentioned is studying a drug called eplontersen for the treatment of ATTR-CM. While Nicotinamide BP is not the main focus of the study, it is included as part of the vitamin supplementation given to patients[1].

The main objectives of this trial are:

  1. To evaluate the long-term safety and tolerability of eplontersen in patients with ATTR-CM
  2. To assess various efficacy parameters after extended dosing with eplontersen

It’s important to note that this trial is an extension study, meaning it follows up on patients who participated in an earlier phase of research[1].

Safety and Side Effects

Nicotinamide BP, as part of a multivitamin supplement, is generally considered safe when taken as directed. However, as with any medication or supplement, there can be potential side effects or interactions. The clinical trial is closely monitoring patients for any adverse events[1].

Important Considerations

If you are considering taking Nicotinamide BP or are participating in a clinical trial involving this supplement, keep the following in mind:

  • Always follow your healthcare provider’s instructions regarding dosage and administration.
  • Inform your doctor about all medications and supplements you are taking to avoid potential interactions.
  • If you experience any unusual symptoms or side effects, report them to your healthcare provider immediately.
  • Remember that while vitamin supplements can be beneficial, they are not a substitute for a balanced diet and healthy lifestyle.

It’s crucial to understand that the information provided here is based on a specific clinical trial and may not apply to all situations. Always consult with a healthcare professional for personalized medical advice[1].

Aspect Details
Study Type Open-label extension study
Main Condition Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Primary Drug Eplontersen
Multivitamin Used Concavit Capsules
Nicotinamide BP Role One of the active substances in Concavit
Administration Route Oral use
Maximum Daily Dose 3000 IU
Maximum Treatment Period 36 months
Primary Objectives Evaluate safety and tolerability of extended eplontersen dosing
Secondary Objectives Assess efficacy parameters and changes in biomarkers

Ongoing Clinical Trials on Nicotinamide Bp

  • Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

    Recruiting

    1 1 1 1
    Austria Belgium Czechia Denmark France Germany +6

Glossary

  • Nicotinamide BP: A form of vitamin B3, also known as niacinamide, which is important for cellular energy production and DNA repair.
  • Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM): A type of heart disease caused by the buildup of abnormal protein deposits (amyloids) in the heart muscle, affecting its function.
  • Eplontersen: The main drug being studied in this clinical trial for the treatment of ATTR-CM.
  • Multivitamin: A supplement containing multiple vitamins and sometimes minerals, designed to provide essential nutrients.
  • Concavit: The brand name of the multivitamin capsule used in this clinical trial, which contains Nicotinamide BP and other vitamins.
  • Open-label extension study: A type of clinical trial where both researchers and participants know which treatment is being given, often following a previous study to gather long-term data.
  • Biomarkers: Measurable indicators in the body that can be used to assess the presence or progress of a disease or the effects of a treatment.
  • Echocardiogram (ECHO): A test that uses sound waves to create images of the heart, allowing doctors to evaluate its structure and function.
  • Quality of Life (QoL) assessment: Questionnaires or tools used to measure a person's overall well-being and ability to function in daily life during a clinical trial.

References

  1. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-eplontersen-for-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/